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Volume 59, Number 6S Abstracts 99SObjectives: To report 30-day results from a prospec-
tive, nonrandomized, multicenter study that evaluated
the safety and effectiveness of the Zenith TX2 Low Pro-
ﬁle Endovascular Graft (TX2-LP, Cook Medical, Bloo-
mington IN) for treatment of blunt thoracic aortic
injuries.
Methods: The TX2-LP device is available in smaller
graft diameters (starting at 18 mm) and lower proﬁle de-
livery systems (starting at 16 Fr) than currently available
thoracic endografts. The device (nitinol stents and poly-
ester graft material) accommodates a tighter aortic curva-
ture (radius of 20 mm) than the predicate TX2 Pro-Form.
Primary endpoint was 30-day mortality.
Results: Between January 2013 and March 2014, 44
patients (40 men; mean age, 43 6 19 years, range, 18-89
years) were treated at 17 US sites. The mean injury
severity score was 30 6 13 (range, 6-66). Technical suc-
cess was achieved in 100% of patients, with 0% intraoper-
ative mortality. Device access was entirely percutaneous
in 17 patients (39%). Smaller size grafts (18-24 mm)
were used in 15 patients (34%). The mean procedure
time was 83 6 46 minutes (range, 34-278 minutes),
and mean blood loss was 109 6 152 cc (range, 0-1000 cc).
The 30-day mortality rate was 2%: one patient died 24
days postprocedure from respiratory failure related to asso-
ciated injuries and not to the device or procedure as adju-
dicated by an independent clinical events committee
(CEC). One patient experienced incomplete quadriplegia
on the day of the procedure (CEC adjudication pending)
and one patient experienced a stroke 7 days postprocedure
(cause undetermined by the CEC). One patient underwent
reintervention for a site-reported proximal type I endoleak
(core lab reported unknown endoleak type) at 30 days
postprocedure. There have been no conversions to open
surgical repair.
Conclusions: Short-term results indicate that the
TX2-LP device appears safe and effective for the treatment
of blunt thoracic aortic injuries. Further enrollment and
follow-up are ongoing.
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West Lafayette, IndyIn memoriamyIn memoriamObjectives: This study reports results of a prospec-
tive, multicenter trial designed to evaluate the safety and
effectiveness of the Zenith Fenestrated AAA Endovascu-
lar Graft (ZFEN, Cook Medical, Bloomington IN) for
treatment of juxtarenal abdominal aortic aneurysms
(AAAs).
Methods: Sixty-seven patients with juxtarenal AAAs
were prospectively enrolled in 14 U.S. centers (2005-
2012). Custom-made fenestrated stent-grafts were
designed with up to three fenestrations based on analysis
of computed tomography (CT) datasets. Renal alignment
was performed using balloon-expandable stents. Follow
up included clinical examination, laboratory studies, duplex
ultrasound, abdominal X-rays and CT imaging at hospital
discharge, 1, 6, 12 months, and yearly thereafter up to 5
years.
Results: here were 54 male and 13 female patients
with a mean age of 7468 years old enrolled. Mean aneu-
rysm diameter was 60 6 10 mm. A total of 178 visceral ar-
teries required incorporation with small fenestrations in
118, scallops in 51 and large fenestrations in 9. Of these,
all 118 small fenestrations (100%), 8 of the scallops
(16%), and 1 of the large fenestrations (11%) were aligned
by stents. Technical success was 100%. There was one post-
operative death within 30 days (1.5%). Mean length of hos-
pital stay was 3 6 2 days. There were no type I or III
endoleaks, aneurysm ruptures or conversions noted during
a mean follow up of 37 6 17 months (3-65 months). Two
patients (3%) had migration >5 mm with no endoleak due
to cranial progression of aortic disease. Of a total of 129
renal arteries targeted by a fenestration, there were 4
(3%) renal artery occlusions and 10 (8%) stenoses. Fifteen
patients (22%) required secondary interventions for renal
artery stenosis/occlusion in 11 patients, type II endoleak
in three and indeterminate endoleak in one. At 5 years, pa-
tient survival was 91% 6 4%, freedom from major adverse
events was 79% 6 6%, primary and secondary patency of
targeted renal arteries was 8165% and 97% 6 2%, freedom
from renal function deterioration was 9165%, and freedom
from secondary interventions was 63% 6 9%.
Conclusions: This prospective study demonstrates
that endovascular repair of juxtarenal AAAs using ZFEN
is safe, effective and durable. Mortality and morbidity are
low in properly selected patients treated in centers with
experience in these procedures.
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